抗うつ薬 (Japanese Wikipedia)

英国国立医療技術評価機構 2011, pp. 1.2.22-1.4.4. 英国国立医療技術評価機構 (2011年1月). Anxiety - Clinical guidelines CG113 (Report). National Institute for Health and Clinical Excellence. 2013年3月10日閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

Moncrieff, Joanna; Kirsch, Irving (2015). “Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences”. Contemporary Clinical Trials 43: 60–62. doi:10.1016/j.cct.2015.05.005. PMID 25979317.
Jakobsen, Janus Christian; Katakam, Kiran Kumar; Schou, Anne; et al. (2017). “Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis”. BMC Psychiatry 17 (1): 58. doi:10.1186/s12888-016-1173-2. PMC 5299662. PMID 28178949.
Zarate, Carlos A.; Singh, Jaskaran B.; Carlson, Paul J.; Brutsche, Nancy E.; Ameli, Rezvan; Luckenbaugh, David A.; Charney, Dennis S.; Manji, Husseini K. (2006). “A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression”. Archives of General Psychiatry 63 (8): 856. doi:10.1001/archpsyc.63.8.856. PMID 16894061.
Insel, T. R.; Wang, P. S. (November 2009). “The STAR*D trial: revealing the need for better treatments”. Psychiatr Serv 60 (11): 1466–7. doi:10.1176/appi.ps.60.11.1466. PMID 19880463.
Pan A, Sun Q, Okereke OI, et al. (January 2012). “Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults”. Diabetologia 55 (1): 63–72. doi:10.1007/s00125-011-2268-4. PMC 3229672. PMID 21811871.
Ross, Joseph S.; Moore, Thomas J.; Glenmullen, Joseph; Furberg, Curt D. (2010). “Prescription Drugs Associated with Reports of Violence Towards Others”. PLoS ONE 5 (12): e15337. doi:10.1371/journal.pone.0015337. PMC 3002271. PMID 21179515.
Jick, Hershel; Kaye J.A., Jick S.S. (2004年7月21日). “Antidepressants and the risk of suicidal behavious”. JAMA 292 (3): 338–343. doi:10.1001/jama.292.3.338. PMID 15265848 2012年11月29日閲覧。.
Bielefeldt, A. O.; Danborg, P. B.; Gotzsche, P. C.; et al. (2016). “Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers”. Journal of the Royal Society of Medicine 109 (10): 381–392. doi:10.1177/0141076816666805. PMC 5066537. PMID 27729596.
Nielsen, Margrethe; Hansen E.H.,Gotzsche P.C. (May 2012). “What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serortonin re-uptake inhibitors”. Addiction 107 (5): 900–908. PMID 21992148.
“Antidepressant discontinuation syndrome”. Am Fam Physician 74 (3): 449–56. (2006). PMID 16913164.
Davies J, Read J (September 2018). “A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?”. Addict Beha. doi:10.1016/j.addbeh.2018.08.027. PMID 30292574.
Hengartner, Michael P. (2017). “Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants’ Efficacy and Harm”. Frontiers in Psychiatry 8: 275. doi:10.3389/fpsyt.2017.00275. PMC 5725408. PMID 29270136.
Miller, G. (July 2010). “Is Pharma Running Out of Brainy Ideas?” (pdf). Science 329 (5991): 502–504. doi:10.1126/science.329.5991.502. PMID 20671165.
Landry, P. (February 1997). “Withdrawal hypomania associated with paroxetine”. J. Clinical Pharmacology 17: 60–61. PMID 9004064.
Stimmel, GL; Dopheide, JA; Stahl, SM (1997). “Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects”. Pharmacotherapy (American College of Clinical Pharmacy) 17 (1): 10–21. PMID 9017762.
Benazzi, F (1997). “Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice”. Journal of Affective Disorders 46 (1): 73–7. doi:10.1016/S0165-0327(97)00082-7. PMID 9387089.
Nakhai-Pour, HR; Broy, P; Bérard, A (2010). “Use of antidepressants during pregnancy and the risk of spontaneous abortion,”. CMAJ : Canadian Medical Association 182 (10): 1031–7. doi:10.1503/cmaj.091208. PMC 2900326. PMID 20513781.
Croen, Lisa A. (November 2011). “Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders”. Archives of General Psychiatry 68 (11): 1104. doi:10.1001/archgenpsychiatry.2011.73. PMID 21727247.
Cohen, MD, Lee S.; Altshuler, LL; Harlow, BL; Nonacs, R; Newport, DJ; Viguera, AC; Suri, R; Burt, VK et al. (2006-02-01). “Relapse of Major Depression During Pregnancy in Women Who Maintain or Discontinue Antidepressant Treatment”. Journal of the American Medical Association (American Medical Association) 295 (5): 499–507. doi:10.1001/jama.295.5.499. PMID 16449615. オリジナルの2007年6月2日時点におけるアーカイブ。 2007年6月14日閲覧。.
Stone M, Laughren T, Jones ML, et al. (2009). “Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration”. BMJ 339: b2880. doi:10.1136/bmj.b2880. PMC 2725270. PMID 19671933.
Griffiths, Joshua J.; Zarate, Carlos A.; Rasimas, J.J.; et al. (2014). “Existing and Novel Biological Therapeutics in Suicide Prevention”. American Journal of Preventive Medicine 47 (3): S195–S203. doi:10.1016/j.amepre.2014.06.012. PMC 4143783. PMID 25145739.
Braun, Cora; Bschor, Tom; Franklin, Jeremy; et al. (2016). “Suicides and Suicide Attempts during Long-Term Treatment with Antidepressants: A Meta-Analysis of 29 Placebo-Controlled Studies Including 6,934 Patients with Major Depressive Disorder”. Psychotherapy and Psychosomatics 85 (3): 171–179. doi:10.1159/000442293. PMID 27043848.
Sharma, Tarang; Guski, Louise Schow; Freund, Nanna; et al. (2016). “Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports”. BMJ (6): i65. doi:10.1136/bmj.i65. PMC 4096990. PMID 24060917.
Hill, Keith D.; Wee, Rohan (January 2012). “Psychotropic Drug-Induced Falls in Older People”. Drugs & Aging 29 (1): 15–30. doi:10.2165/11598420-000000000-00000. PMID 22191720.
Chang, Chia-Ming; Wu, Erin Chia-Hsuan; Chen, Chuan-Yu; Wu, Kuan-Yi; Liang, Hsin-Yi; Chau, Yeuk-Lun; Wu, Chi-Shin; Lin, Keh-Ming et al. (September 2012). “Psychotropic Drugs and Risk of Motor Vehicle Accidents: a Population-based Case-Control Study”. British Journal of Clinical Pharmacology: n/a–n/a. doi:10.1111/j.1365-2125.2012.04410.x. PMID 22971090.
Vertes, Robert P.; Eastman, KE (2000). “The case against memory consolidation in REM sleep”. Behavioral and Brain Sciences 23 (6): 867–876. doi:10.1017/S0140525X00004003. PMID 11515146.
Tamam, L.; Ozpoyraz N. (2002). “Selective serotonin reuptake inhibitor discontinuation syndrome: a review.”. Adv Ther. 19 (1): 17–26. doi:10.1007/BF02850015. PMID 12008858.
Uz T, Ahmed R, Akhisaroglu M, Kurtuncu M, Imbesi M, Dirim Arslan A, Manev H (2005). “Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum”. Neuroscience 134 (4): 1309–16. doi:10.1016/j.neuroscience.2005.05.003. PMID 15994025.
Yuferov V, Butelman E, Kreek M (2005). “Biological clock: biological clocks may modulate drug addiction”. Eur J Hum Genet 13 (10): 1101–3. doi:10.1038/sj.ejhg.5201483. PMID 16094306.
Manev H, Uz T (2006). “Clock genes as a link between addiction and obesity”. Eur J Hum Genet 14 (1): 5. doi:10.1038/sj.ejhg.5201524. PMID 16288309.
Baboolal N (2004). “Venlafaxine withdrawal syndrome: report of seven cases in Trinidad”. J Clin Psychopharmacol 24 (2): 229–31. doi:10.1097/01.jcp.0000117427.05703.f2. PMID 15206672.
Reeves R, Mack J, Beddingfield J (2003). “Shock-like sensations during venlafaxine withdrawal”. Pharmacotherapy 23 (5): 678–81. doi:10.1592/phco.23.5.678.32198. PMID 12741444.
Haddad P (2001). “Antidepressant discontinuation syndromes”. Drug Saf 24 (3): 183–97. doi:10.2165/00002018-200124030-00003. PMID 11347722.
Fava M, Mulroy R, Alpert J, Nierenberg A, Rosenbaum J (1997). “Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine”. Am J Psychiatry 154 (12): 1760–2. PMID 9396960.
Parker G, Blennerhassett J (1998). “Withdrawal reactions associated with venlafaxine”. Aust N Z J Psychiatry 32 (2): 291–4. doi:10.3109/00048679809062742. PMID 9588310.
van Noorden M, Vergouwen A, Koerselman G (2002). “[Delirium during withdrawal of venlafaxine]”. Ned Tijdschr Geneeskd 146 (26): 1236–7. PMID 12132141.
Nissen C, Feige B, Nofzinger E, Riemann D, Berger M, Voderholzer U (2005). “Transient narcolepsy-cataplexy syndrome after discontinuation of the antidepressant venlafaxine”. J Sleep Res 14 (2): 207–8. doi:10.1111/j.1365-2869.2005.00447.x. PMID 15910521.
Agelink M, Zitzelsberger A, Klieser E (1997). “Withdrawal syndrome after discontinuation of venlafaxine”. Am J Psychiatry 154 (10): 1473–4. PMID 9326838.
Hamilton, M (1960). “A rating scale for depression.”. Journal of Neurology, Neurosurgery and Psychiatry 23: 56–62. doi:10.1136/jnnp.23.1.56. PMID 14399272.
Trivedi MH, Fava M, Wisniewski SR (2006年3月23日). “Medication augmentation after the failure of SSRIs for depression”. N. Engl. J. Med. 354 (12): 1243–52. doi:10.1056/NEJMoa052964. PMID 16554526.
Trivedi MH, Rush AJ, Wisniewski SR (2006). “Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice”. The American Journal of Psychiatry 163 (1): 28–40. doi:10.1176/appi.ajp.163.1.28. PMID 16390886.
Rush AJ, Trivedi MH, Wisniewski SR (2006). “Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression”. N. Engl. J. Med. 354 (12): 1231–42. doi:10.1056/NEJMoa052963. PMID 16554525.
Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z (2005). “Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant Action: Systematic Review and Meta-analysis”. Arch Gen Psychiatry 63 (11): 1217–23. doi:10.1001/archpsyc.63.11.1217. PMC 2211759. PMID 17088502.
Gueorguieva, Ralitza (December 2011). “Trajectories of Depression Severity in Clinical Trials of Duloxetine Insights Into Antidepressant and Placebo Responses”. Archives of General Psychiatry 68 (12): 1227–37. doi:10.1001/archgenpsychiatry.2011.132. PMC 3339151. PMID 22147842.
Jureidini, Jon N.; Doecke, Christopher J.; Mansfield, Peter R.; Haby, Michelle M.; Menkes, David B.; Tonkin, Anne L. (2004). “Efficacy and safety of antidepressants for children and adolescents”. BMJ 328 (7444): 879–83. doi:10.1136/bmj.328.7444.879. PMC 387483. PMID 15073072.
Lakhan, Shaheen E.; Hagger-Johnson, Gareth E. (2007). “The impact of prescribed psychotropics on youth”. Clinical practice and epidemiology in mental health 3: 21. doi:10.1186/1745-0179-3-21. PMC 2100041. PMID 17949504.
Moncrieff, Joanna; Wessely, Simon; Hardy, Rebecca; Moncrieff, Joanna (2004). Moncrieff, Joanna. ed. “Active placebos versus antidepressants for depression”. Cochrane database of systematic reviews (Online) (1): CD003012. doi:10.1002/14651858.CD003012.pub2. PMID 14974002.
Anderson IM (April 2000). “Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability”. J Affect Disord 58 (1): 19–36. doi:10.1016/S0165-0327(99)00092-0. PMID 10760555.
MacGillivray, Steve; Hatcher, Simon; Ogston, Simon; Reid, Ian; Sullivan, Frank; Williams, Brian; Crombie, Iain; Crombie, I (2003). “Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis”. BMJ 326 (7397): 1014. doi:10.1136/bmj.326.7397.1014. PMC 154760. PMID 12742924.
Parker G, Roy K, Wilhelm K, Mitchell P (February 2001). “Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study”. J Clin Psychiatry 62 (2): 117–25. doi:10.4088/JCP.v62n0209. PMID 11247097.
Lotufo-Neto, Francisco; Trivedi, Madhukar; Thase, Michael E. (1999). “Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression”. Neuropsychopharmacology 20 (3): 226–47. doi:10.1016/S0893-133X(98)00075-X. PMID 10063483.
Ruhe, H. G.; Huyser, J.; Swinkels, J. A.; Schene, A. H. (October 2006). “Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: Systematic review”. The British Journal of Psychiatry 189 (4): 309–316. doi:10.1192/bjp.bp.105.018325. PMID 17012653.
“Dose-escalation of SSRIS in major depressive disorder. Should not be recommended in current guidelines”. Tijdschrift Voor Psychiatrie 52 (9): 615–25. (2010). PMID 20862644.
Papakostas, George I.; Charles, Dana; Fava, Maurizio (March 2010). “Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder”. World Journal of Biological Psychiatry 11 (2_2): 300–307. doi:10.3109/15622970701432528. PMID 20218793.
Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C (April 1999). “Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials”. The British Journal of Psychiatry : the Journal of Mental Science 174: 297–303. doi:10.1192/bjp.174.4.297. PMID 10533547.
Baghai TC, Möller HJ, Rupprecht R (2006). “Recent progress in pharmacological and non-pharmacological treatment options of major depression”. Curr. Pharm. Des. 12 (4): 503–15. doi:10.2174/138161206775474422. PMID 16472142.
Ruhé HG, Huyser J, Swinkels JA, Schene AH (December 2006). “Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review”. J Clin Psychiatry 67 (12): 1836–55. doi:10.4088/JCP.v67n1203. PMID 17194261.
Tranter R, O'Donovan C, Chandarana P, Kennedy S (July 2002). “Prevalence and outcome of partial remissionin depression”. J Psychiatry Neurosci 27 (4): 241–7. PMC 161658. PMID 12174733.
Byrne SE, Rothschild AJ (June 1998). “Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments”. J Clin Psychiatry 59 (6): 279–88. doi:10.4088/JCP.v59n0602. PMID 9671339.
Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M (June 2000). “Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians”. Can J Psychiatry 45 (5): 476–81. PMID 10900529.
Tansey KE, Guipponi M, Perroud N, et al. (October 2012). “Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis”. PLoS Medicine 9 (10): e1001326. doi:10.1371/journal.pmed.1001326. PMC 3472989. PMID 23091423.
Bschor T., Baethge C. (2010). “No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy”. Acta Psychiatrica Scandinavica 121 (3): 174–179. doi:10.1111/j.1600-0447.2009.01458.x. PMID 19703121.
DeBattista C, Lembke A (December 2005). “Update on augmentation of antidepressant response in resistant depression”. Curr Psychiatry Rep 7 (6): 435–40. doi:10.1007/s11920-005-0064-x. PMID 16318821.
Lam RW, Wan DD, Cohen NL, Kennedy SH (August 2002). “Combining antidepressants for treatment-resistant depression: a review”. J Clin Psychiatry 63 (8): 685–93. doi:10.4088/JCP.v63n0805. PMID 12197448.
Rapaport, Mark Hyman; Gharabawi, Georges M; Canuso, Carla M; Mahmoud, Ramy A; Keller, Martin B; Bossie, Cynthia A; Turkoz, Ibrahim; Lasser, Robert A et al. (November 2006). “Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation”. Neuropsychopharmacology 31 (11): 2505–2513. doi:10.1038/sj.npp.1301113. PMID 16760927.
Geddes JR, Carney SM, Davies C (February 2003). “Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review”. Lancet 361 (9358): 653–61. doi:10.1016/S0140-6736(03)12599-8. PMID 12606176.
Bockting, Claudi L.H.; ten Doesschate, Mascha C.; Spijker, Jan; et al. (2008). “Continuation and Maintenance Use of Antidepressants in Recurrent Depression”. Psychotherapy and Psychosomatics 77 (1): 17–26. doi:10.1159/000110056. PMID 18087204.
Fava GA, Park SK, Sonino N (November 2006). “Treatment of recurrent depression”. Expert Rev Neurother 6 (11): 1735–40. doi:10.1586/14737175.6.11.1735. PMID 17144786.
Petersen TJ (May 2006). “Enhancing the efficacy of antidepressants with psychotherapy”. J. Psychopharmacol. (Oxford) 20 (3 Suppl): 19–28. doi:10.1177/1359786806064314. PMID 16644768.
Fava, G. A. (October 2004). “Six-Year Outcome of Cognitive Behavior Therapy for Prevention of Recurrent Depression”. American Journal of Psychiatry 161 (10): 1872–1876. doi:10.1176/appi.ajp.161.10.1872. PMID 15465985.
Baldessarini, Ross J.; Tondo, Leonardo; Ghiani, Carmen; et al. (2010). “Illness Risk Following Rapid Versus Gradual Discontinuation of Antidepressants”. American Journal of Psychiatry 167 (8): 934–941. doi:10.1176/appi.ajp.2010.09060880. PMID 20478876.
Bian ZX, Wu TX (2010). “Legislation for trial registration and data transparency”. Trials 11: 64. doi:10.1186/1745-6215-11-64. PMC 2882906. PMID 20504337.
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (February 2008). “Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration”. PLoS Medicine 5 (2): e45. doi:10.1371/journal.pmed.0050045. PMC 2253608. PMID 18303940.
Barbui C, Furukawa TA, Cipriani A (January 2008). “Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials”. CMAJ 178 (3): 296–305. doi:10.1503/cmaj.070693. PMC 2211353. PMID 18227449.
Melander H, Salmonson T, Abadie E, van Zwieten-Boot B. (September 2008). “A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 18 (9): 623–7. doi:10.1016/j.euroneuro.2008.06.003. PMID 18621509.
Fazeli, Pouneh K.; Calder, Genevieve L.; Miller, Karen K.; Misra, Madhusmita; Lawson, Elizabeth A.; Meenaghan, Erinne; Lee, Hang; Herzog, David et al. (December 2012). “Psychotropic medication use in anorexia nervosa between 1997 and 2009”. International Journal of Eating Disorders 45 (8): 970–976. doi:10.1002/eat.22037. PMID 22733643.
Schildkraut, J.J. (1965-05-01). “The Catecholamine Hypothesis of Affective Disorders: A Review of Supporting Evidence”. American Journal Of Psychiatry 122 (5): 519-22. PMID 5319766.
Pletscher, A.; Shore, P. A.; Brodie, B. B. (August 1955). “Serotonin Release as a Possible Mechanism of Reserpine Action”. Science 122 (3165): 374–375. doi:10.1126/science.122.3165.374. PMID 13246642.
Davies, D.L.; Shepherd, Michael (July 1955). “Reserpine in the treatment of anxious and depressed patients”. The Lancet 266 (6881): 117–120. doi:10.1016/S0140-6736(55)92118-8. PMID 14392947.
Wallace, D.C. (July 1955). “Treatment of Hypertension Hypotensive Drugs and Mental Changes”. The Lancet 266 (6881): 116–117. doi:10.1016/S0140-6736(55)92117-6. PMID 14392946.
Nutt, David (2014). “Help luck along to find psychiatric medicines”. Nature 515 (7526): 165–165. doi:10.1038/515165a. PMID 25391924.
Nutt, David J; Carhart-Harris, Robin L; Bolstridge, Mark; et al. (2016). “Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study”. The Lancet Psychiatry 3 (7): 619–627. doi:10.1016/S2215-0366(16)30065-7. PMID 27210031.
Appleton KM, Sallis HM, Perry R, Ness AR, Churchill R (November 2015). “Omega-3 fatty acids for depression in adults”. Cochrane Database Syst Re (11): CD004692. doi:10.1002/14651858.CD004692.pub4. PMC 5321518. PMID 26537796.
Mocking RJ, Harmsen I, Assies J, Koeter MW, Ruhé HG, Schene AH (March 2016). “Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder”. Transl Psychiatry: e756. doi:10.1038/tp.2016.29. PMC 4872453. PMID 26978738. https://doi.org/10.1038/tp.2016.29.
Galizia I, Oldani L, Macritchie K, et al. (October 2016). “S-adenosyl methionine (SAMe) for depression in adults”. Cochrane Database Syst Re: CD011286. doi:10.1002/14651858.CD011286.pub2. PMID 27727432.
Veronese N, Stubbs B, Solmi M, Ajnakina O, Carvalho AF, Maggi S (2018). “Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis”. Psychosom Med (2): 154–159. doi:10.1097/PSY.0000000000000537. PMID 29076953.
Bersani G, Meco G, Denaro A, et al. (October 2013). “L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine”. Eur Neuropsychopharmacol (10): 1219–25. doi:10.1016/j.euroneuro.2012.11.013. PMID 23428336.
Chiechio S, Canonico PL, Grilli M (December 2017). “l-Acetylcarnitine: A Mechanistically Distinctive and Potentially Rapid-Acting Antidepressant Drug”. Int J Mol Sci (1). doi:10.3390/ijms19010011. PMC 5795963. PMID 29267192.
“Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials”. J Affect Disord 227: 219–225. (2017-10-28). doi:10.1016/j.jad.2017.10.042. PMID 29102836.
“Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness”. J Affect Disord 208: 22–32. (2017). doi:10.1016/j.jad.2016.09.012. PMID 27744123.
“Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder”. Biological psychiatry 59 (3). (2006). doi:10.1016/j.biopsych.2005.07.013. PMID 16248986.

pmc.ncbi.nlm.nih.gov

Jakobsen, Janus Christian; Katakam, Kiran Kumar; Schou, Anne; et al. (2017). “Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis”. BMC Psychiatry 17 (1): 58. doi:10.1186/s12888-016-1173-2. PMC 5299662. PMID 28178949.
Pan A, Sun Q, Okereke OI, et al. (January 2012). “Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults”. Diabetologia 55 (1): 63–72. doi:10.1007/s00125-011-2268-4. PMC 3229672. PMID 21811871.
Ross, Joseph S.; Moore, Thomas J.; Glenmullen, Joseph; Furberg, Curt D. (2010). “Prescription Drugs Associated with Reports of Violence Towards Others”. PLoS ONE 5 (12): e15337. doi:10.1371/journal.pone.0015337. PMC 3002271. PMID 21179515.
Bielefeldt, A. O.; Danborg, P. B.; Gotzsche, P. C.; et al. (2016). “Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers”. Journal of the Royal Society of Medicine 109 (10): 381–392. doi:10.1177/0141076816666805. PMC 5066537. PMID 27729596.
Hengartner, Michael P. (2017). “Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants’ Efficacy and Harm”. Frontiers in Psychiatry 8: 275. doi:10.3389/fpsyt.2017.00275. PMC 5725408. PMID 29270136.
Nakhai-Pour, HR; Broy, P; Bérard, A (2010). “Use of antidepressants during pregnancy and the risk of spontaneous abortion,”. CMAJ : Canadian Medical Association 182 (10): 1031–7. doi:10.1503/cmaj.091208. PMC 2900326. PMID 20513781.
Stone M, Laughren T, Jones ML, et al. (2009). “Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration”. BMJ 339: b2880. doi:10.1136/bmj.b2880. PMC 2725270. PMID 19671933.
Griffiths, Joshua J.; Zarate, Carlos A.; Rasimas, J.J.; et al. (2014). “Existing and Novel Biological Therapeutics in Suicide Prevention”. American Journal of Preventive Medicine 47 (3): S195–S203. doi:10.1016/j.amepre.2014.06.012. PMC 4143783. PMID 25145739.
Sharma, Tarang; Guski, Louise Schow; Freund, Nanna; et al. (2016). “Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports”. BMJ (6): i65. doi:10.1136/bmj.i65. PMC 4096990. PMID 24060917.
Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z (2005). “Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant Action: Systematic Review and Meta-analysis”. Arch Gen Psychiatry 63 (11): 1217–23. doi:10.1001/archpsyc.63.11.1217. PMC 2211759. PMID 17088502.
Gueorguieva, Ralitza (December 2011). “Trajectories of Depression Severity in Clinical Trials of Duloxetine Insights Into Antidepressant and Placebo Responses”. Archives of General Psychiatry 68 (12): 1227–37. doi:10.1001/archgenpsychiatry.2011.132. PMC 3339151. PMID 22147842.
Jureidini, Jon N.; Doecke, Christopher J.; Mansfield, Peter R.; Haby, Michelle M.; Menkes, David B.; Tonkin, Anne L. (2004). “Efficacy and safety of antidepressants for children and adolescents”. BMJ 328 (7444): 879–83. doi:10.1136/bmj.328.7444.879. PMC 387483. PMID 15073072.
Lakhan, Shaheen E.; Hagger-Johnson, Gareth E. (2007). “The impact of prescribed psychotropics on youth”. Clinical practice and epidemiology in mental health 3: 21. doi:10.1186/1745-0179-3-21. PMC 2100041. PMID 17949504.
MacGillivray, Steve; Hatcher, Simon; Ogston, Simon; Reid, Ian; Sullivan, Frank; Williams, Brian; Crombie, Iain; Crombie, I (2003). “Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis”. BMJ 326 (7397): 1014. doi:10.1136/bmj.326.7397.1014. PMC 154760. PMID 12742924.
Tranter R, O'Donovan C, Chandarana P, Kennedy S (July 2002). “Prevalence and outcome of partial remissionin depression”. J Psychiatry Neurosci 27 (4): 241–7. PMC 161658. PMID 12174733.
Tansey KE, Guipponi M, Perroud N, et al. (October 2012). “Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis”. PLoS Medicine 9 (10): e1001326. doi:10.1371/journal.pmed.1001326. PMC 3472989. PMID 23091423.
Bian ZX, Wu TX (2010). “Legislation for trial registration and data transparency”. Trials 11: 64. doi:10.1186/1745-6215-11-64. PMC 2882906. PMID 20504337.
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (February 2008). “Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration”. PLoS Medicine 5 (2): e45. doi:10.1371/journal.pmed.0050045. PMC 2253608. PMID 18303940.
Barbui C, Furukawa TA, Cipriani A (January 2008). “Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials”. CMAJ 178 (3): 296–305. doi:10.1503/cmaj.070693. PMC 2211353. PMID 18227449.
Appleton KM, Sallis HM, Perry R, Ness AR, Churchill R (November 2015). “Omega-3 fatty acids for depression in adults”. Cochrane Database Syst Re (11): CD004692. doi:10.1002/14651858.CD004692.pub4. PMC 5321518. PMID 26537796.
Mocking RJ, Harmsen I, Assies J, Koeter MW, Ruhé HG, Schene AH (March 2016). “Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder”. Transl Psychiatry: e756. doi:10.1038/tp.2016.29. PMC 4872453. PMID 26978738. https://doi.org/10.1038/tp.2016.29.
Chiechio S, Canonico PL, Grilli M (December 2017). “l-Acetylcarnitine: A Mechanistically Distinctive and Potentially Rapid-Acting Antidepressant Drug”. Int J Mol Sci (1). doi:10.3390/ijms19010011. PMC 5795963. PMID 29267192.

ncbi.nlm.nih.gov

Pan A, Sun Q, Okereke OI, et al. (January 2012). “Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults”. Diabetologia 55 (1): 63–72. doi:10.1007/s00125-011-2268-4. PMC 3229672. PMID 21811871.
Landry, P. (February 1997). “Withdrawal hypomania associated with paroxetine”. J. Clinical Pharmacology 17: 60–61. PMID 9004064.
Nakhai-Pour, HR; Broy, P; Bérard, A (2010). “Use of antidepressants during pregnancy and the risk of spontaneous abortion,”. CMAJ : Canadian Medical Association 182 (10): 1031–7. doi:10.1503/cmaj.091208. PMC 2900326. PMID 20513781.
Lanza di Scalea, T; Wisner KL (September 2009). “Antidepressant medication use during breastfeeding”. Clin Obstet Gynecol 52 (3): 483–9 2012年11月29日閲覧。.
Stone M, Laughren T, Jones ML, et al. (2009). “Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration”. BMJ 339: b2880. doi:10.1136/bmj.b2880. PMC 2725270. PMID 19671933.
Griffiths, Joshua J.; Zarate, Carlos A.; Rasimas, J.J.; et al. (2014). “Existing and Novel Biological Therapeutics in Suicide Prevention”. American Journal of Preventive Medicine 47 (3): S195–S203. doi:10.1016/j.amepre.2014.06.012. PMC 4143783. PMID 25145739.
Sharma, Tarang; Guski, Louise Schow; Freund, Nanna; et al. (2016). “Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports”. BMJ (6): i65. doi:10.1136/bmj.i65. PMC 4096990. PMID 24060917.
Maund, E.; Schow Guski, L.; Gotzsche, P. C. (2016). “Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports”. Canadian Medical Association Journal. doi:10.1503/cmaj.151104.
Fava, GA; Bernardi M, Tomba E, Rafanelli C. (December 2007). “Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia”. Int. J. Neuropsychopharmacology 10 (6): 835–838.
Warden, Diane; Rush AJ, Trivedi MH, Fava M, Wisniewski SR (Dec 2007). “The STAR*D Project results: a comprehensive review of findings.”. Curr Psychiatry Rep 9 (6): 449–59 2012年11月28日閲覧。.
Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z (2005). “Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant Action: Systematic Review and Meta-analysis”. Arch Gen Psychiatry 63 (11): 1217–23. doi:10.1001/archpsyc.63.11.1217. PMC 2211759. PMID 17088502.
Holtzheimer, Paul; Mayberg, Helen S. (January 2011). “Stuck in a Rut: Rethinking Depression and its Treatment”. Trends Neurosci. 34 (1): 1–9. doi:10.1016/j.tins.2010.10.004 2012年11月29日閲覧。.
Jureidini, Jon N.; Doecke, Christopher J.; Mansfield, Peter R.; Haby, Michelle M.; Menkes, David B.; Tonkin, Anne L. (2004). “Efficacy and safety of antidepressants for children and adolescents”. BMJ 328 (7444): 879–83. doi:10.1136/bmj.328.7444.879. PMC 387483. PMID 15073072.
Lakhan, Shaheen E.; Hagger-Johnson, Gareth E. (2007). “The impact of prescribed psychotropics on youth”. Clinical practice and epidemiology in mental health 3: 21. doi:10.1186/1745-0179-3-21. PMC 2100041. PMID 17949504.
MacGillivray, Steve; Hatcher, Simon; Ogston, Simon; Reid, Ian; Sullivan, Frank; Williams, Brian; Crombie, Iain; Crombie, I (2003). “Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis”. BMJ 326 (7397): 1014. doi:10.1136/bmj.326.7397.1014. PMC 154760. PMID 12742924.
Tranter R, O'Donovan C, Chandarana P, Kennedy S (July 2002). “Prevalence and outcome of partial remissionin depression”. J Psychiatry Neurosci 27 (4): 241–7. PMC 161658. PMID 12174733.
Tansey KE, Guipponi M, Perroud N, et al. (October 2012). “Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis”. PLoS Medicine 9 (10): e1001326. doi:10.1371/journal.pmed.1001326. PMC 3472989. PMID 23091423.
Chouinard, Guy; Chouinard Virginie-Anne (January 2008). “Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes”. Psychother Psychosom 77 (7): 69–77 2012年11月29日閲覧。.
Gardarsdottir, H; van Geffen EC, Stolker JJ, Egberts TC, Heerdink ER (Feb 2009). “Does the length of the first antidepressant treatment episode influence risk and time to a second episode?”. J Clin Psychopharmacol. 29 (1): 69–72 2012年11月29日閲覧。.
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (February 2008). “Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration”. PLoS Medicine 5 (2): e45. doi:10.1371/journal.pmed.0050045. PMC 2253608. PMID 18303940.
Barbui C, Furukawa TA, Cipriani A (January 2008). “Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials”. CMAJ 178 (3): 296–305. doi:10.1503/cmaj.070693. PMC 2211353. PMID 18227449.

nimh.nih.gov

“Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study”. National Institute of Mental Health. 2012年11月28日閲覧。

nii.ac.jp

kaken.nii.ac.jp

KAKEN (2015), 膜輸送体OCTN1による神経細胞の機能制御機構とうつ病治療への応用に関する研究

nytimes.com

patient.co.uk

“SSRI Antidepressants | Health”. Patient.co.uk (2010年10月27日). 2012年11月30日閲覧。

paxilprogress.org

“Paxil Progress”. 2012年11月27日閲覧。

plosmedicine.org

Hay, Phillipa J.; Spielmans, Glen I.; Berman, Margit I.; Linardatos, Eftihia; Rosenlicht, Nicholas Z.; Perry, Angela; Tsai, Alexander C. (2013). “Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes”. PLoS Medicine 10 (3): e1001403. doi:10.1371/journal.pmed.1001403.

plosone.org

Ross, Joseph S.; Moore, Thomas J.; Glenmullen, Joseph; Furberg, Curt D. (2010). “Prescription Drugs Associated with Reports of Violence Towards Others”. PLoS ONE 5 (12): e15337. doi:10.1371/journal.pone.0015337. PMC 3002271. PMID 21179515.
Khan, Arif; Faucett, J., Lichtenberg P., Kirsch I., Brown W.A. (2012年7月30日). “A Systematic Review of Comparative Efficacy of Treatments and Controls for Depression”. PLoS One: e41778. doi:10.1371/journal.pone.0041778 2012年11月28日閲覧。.

pmda.go.jp

info.pmda.go.jp

"SSRI/SNRIと他害行為について". 医薬品・医療機器等安全性情報PMDSI No261 (pdf) (Report). 医薬品医療機器総合機構. 2009年9月. pp. 8–12. 2013年2月23日閲覧。
エビリファイ添付文書 Archived 2013年10月23日, at the Wayback Machine.

post-gazette.com

David Armstrong, "Drug Interactions: Financial Ties to Industry Cloud Major Depression Study At Issue: Whether It's Safe For Pregnant Women To Stay on Medication - JAMA Asks Authors to Explain". Wall Street Journal. July 11, 2006 (copy published on post-gazette.com)

pslgroup.com

“ISP: Mirtazapine Regulates Stress Hormones, Improves Sleep In Depressed Patients”. 2013年1月19日閲覧。

psychiatryonline.org

ajp.psychiatryonline.org

Fava, Maurizio; et al (2006). “A Compariそのson of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report”. Am J Psychiatry 163: number 7: 1161–1172 2012年11月28日閲覧。.
Fava, G. A. (October 2004). “Six-Year Outcome of Cognitive Behavior Therapy for Prevention of Recurrent Depression”. American Journal of Psychiatry 161 (10): 1872–1876. doi:10.1176/appi.ajp.161.10.1872. PMID 15465985.
Baldessarini, Ross J.; Tondo, Leonardo; Ghiani, Carmen; et al. (2010). “Illness Risk Following Rapid Versus Gradual Discontinuation of Antidepressants”. American Journal of Psychiatry 167 (8): 934–941. doi:10.1176/appi.ajp.2010.09060880. PMID 20478876.

ps.psychiatryonline.org

Insel, T. R.; Wang, P. S. (November 2009). “The STAR*D trial: revealing the need for better treatments”. Psychiatr Serv 60 (11): 1466–7. doi:10.1176/appi.ps.60.11.1466. PMID 19880463.

psychologicalscience.org

“Hollon SD, Thase ME, Markowitz JC. "Treatment and prevention of depression", ''Psychological Science in the Public Interest'', 2002;3:1–39.” (PDF). 2012年11月30日閲覧。

reuters.com

Kate Kelland; Ben Hirschler (2012年3月). “Insight: Antidepressants give drugmakers the blues”. Reuters 2013年1月29日閲覧。

sagepub.com

journals.sagepub.com

Bielefeldt, A. O.; Danborg, P. B.; Gotzsche, P. C.; et al. (2016). “Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers”. Journal of the Royal Society of Medicine 109 (10): 381–392. doi:10.1177/0141076816666805. PMC 5066537. PMID 27729596.

secretariat.ne.jp

日本うつ病学会 & 気分障害のガイドライン作成委員会 2012, pp. 20–25. 日本うつ病学会、気分障害のガイドライン作成委員会『日本うつ病学会治療ガイドライン II.大うつ病性障害2012 Ver.1 (pdf)』（レポート）（2012 Ver.1版）、日本うつ病学会、気分障害のガイドライン作成委員会、2012年7月26日。2013年1月1日閲覧。
日本うつ病学会 & 気分障害のガイドライン作成委員会 2013, pp. 22–27. 日本うつ病学会、気分障害のガイドライン作成委員会『日本うつ病学会治療ガイドライン II.大うつ病性障害2013 Ver.1.1 (pdf)』（レポート）（2012 Ver.1.1版）、日本うつ病学会、気分障害のガイドライン作成委員会、2013年9月24日。2013年1月1日閲覧。
日本うつ病学会 & 気分障害のガイドライン作成委員会 2012, pp. 20–26. 日本うつ病学会、気分障害のガイドライン作成委員会『日本うつ病学会治療ガイドライン II.大うつ病性障害2012 Ver.1 (pdf)』（レポート）（2012 Ver.1版）、日本うつ病学会、気分障害のガイドライン作成委員会、2012年7月26日。2013年1月1日閲覧。
日本うつ病学会 & 気分障害のガイドライン作成委員会 2013, pp. 22–28. 日本うつ病学会、気分障害のガイドライン作成委員会『日本うつ病学会治療ガイドライン II.大うつ病性障害2013 Ver.1.1 (pdf)』（レポート）（2012 Ver.1.1版）、日本うつ病学会、気分障害のガイドライン作成委員会、2013年9月24日。2013年1月1日閲覧。
日本うつ病学会 & 気分障害のガイドライン作成委員会 2012, pp. 26–28. 日本うつ病学会、気分障害のガイドライン作成委員会『日本うつ病学会治療ガイドライン II.大うつ病性障害2012 Ver.1 (pdf)』（レポート）（2012 Ver.1版）、日本うつ病学会、気分障害のガイドライン作成委員会、2012年7月26日。2013年1月1日閲覧。
日本うつ病学会 & 気分障害のガイドライン作成委員会 2013, pp. 28–30. 日本うつ病学会、気分障害のガイドライン作成委員会『日本うつ病学会治療ガイドライン II.大うつ病性障害2013 Ver.1.1 (pdf)』（レポート）（2012 Ver.1.1版）、日本うつ病学会、気分障害のガイドライン作成委員会、2013年9月24日。2013年1月1日閲覧。
日本うつ病学会 & 気分障害のガイドライン作成委員会 2013, pp. 32–36. 日本うつ病学会、気分障害のガイドライン作成委員会『日本うつ病学会治療ガイドライン II.大うつ病性障害2013 Ver.1.1 (pdf)』（レポート）（2012 Ver.1.1版）、日本うつ病学会、気分障害のガイドライン作成委員会、2013年9月24日。2013年1月1日閲覧。
日本うつ病学会 & 気分障害のガイドライン作成委員会 2012. 日本うつ病学会、気分障害のガイドライン作成委員会『日本うつ病学会治療ガイドライン II.大うつ病性障害2012 Ver.1 (pdf)』（レポート）（2012 Ver.1版）、日本うつ病学会、気分障害のガイドライン作成委員会、2012年7月26日。2013年1月1日閲覧。
野村総一郎「抗うつ薬で自殺が増加するか？ (PDF) 」（日本うつ病学会、2007年9月14日）
渡邊衡一郎「自殺予防のために薬物療法によってできることは何か (PDF) 」（日本うつ病学会、シンポジウム開催年2012年）
日本うつ病学会 & 気分障害のガイドライン作成委員会 2012, p. 24. 日本うつ病学会、気分障害のガイドライン作成委員会『日本うつ病学会治療ガイドライン II.大うつ病性障害2012 Ver.1 (pdf)』（レポート）（2012 Ver.1版）、日本うつ病学会、気分障害のガイドライン作成委員会、2012年7月26日。2013年1月1日閲覧。
日本うつ病学会 & 気分障害のガイドライン作成委員会 2013, p. 34. 日本うつ病学会、気分障害のガイドライン作成委員会『日本うつ病学会治療ガイドライン II.大うつ病性障害2013 Ver.1.1 (pdf)』（レポート）（2012 Ver.1.1版）、日本うつ病学会、気分障害のガイドライン作成委員会、2013年9月24日。2013年1月1日閲覧。